The Safety, Feasibility, and Repeatability of Inhaled Adenosine 5'-Triphosphate Cough Challenges in Adults with Chronic Cough and Mild Asthma

What this Trial Is About

Researchers are evaluating the safety, feasibility, and repeatability of inhaled adenosine 5'-triphosphate (ATP) cough challenges in healthy adults, patients with mild asthma, and those with chronic cough. This phase 1 study aims to better understand how these challenges can measure cough sensitivity and help identify patients who might respond to therapies targeting ATP. The study is sponsored by McMaster University and includes adults aged 18 and older. Participants will inhale increasing doses of ATP dissolved in saline through a vibrating mesh nebulizer. The study will observe reactions to these doses, including lung function changes and symptoms like wheeze, chest tightness, and shortness of breath. The study includes repeat ATP cough challenges within one week to assess consistency and will monitor for any adverse events throughout the process. During the study, participants will undergo spirometry to measure lung function and report symptoms using the mBorg scale. Oxygen saturation will also be monitored. Researchers will record cough counts and the doses of ATP that trigger specific cough responses. The study involves careful monitoring until the end of the ATP challenge and follow-up for one week to gather safety and repeatability data. Participation duration varies based on individual procedures.

The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges